

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Actinogen Medical Limited</b>
<b>ABN</b>	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Dr Geoffrey Brooke</b>
<b>Date of last notice</b>	<b>1 December 2023</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	1. Direct 2. Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	2. HSBC Custody Nominees (Australia) Limited <A/C 2> - beneficiary
<b>Date of change</b>	5 June 2024
<b>No. of securities held prior to change</b>	1. 14,500,000 fully paid ordinary shares issued pursuant to Employee Share Loan Plan. 550,661 fully paid ordinary shares 275,331 unlisted options ex @ \$0.0375 exp 11/9/2026 5,000,000 unlisted options ex @ \$0.10 exp 24/3/2025. 2. 2,626,280 fully paid ordinary shares. 237,029 unlisted options ex @ \$0.0375 exp 11/9/2026
<b>Class</b>	Fully paid ordinary shares Unlisted options ex @ \$0.05 exp 31/5/2027
<b>Number acquired</b>	1. 1,003,378 fully paid ordinary shares 501,689 unlisted options ex @ \$0.05 exp 31/5/2027 2. 175,085 fully paid ordinary shares 87,543 unlisted options ex @ \$0.05 exp 31/5/2027
<b>Number disposed</b>	-

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration includes brokerage/gst</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$29,461.58
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>14,500,000 fully paid ordinary shares issued pursuant to Employee Share Loan Plan.  1,554,039 fully paid ordinary shares  5,000,000 unlisted options ex @ \$0.10 exp 24/3/2025  275,331 unlisted options ex @ \$0.0375 exp 11/9/2026  501,689 unlisted options ex @ \$0.05 exp 31/5/2027</li> <li>2,801,365 fully paid ordinary shares.  237,029 unlisted options ex @ \$0.0375 exp 11/9/2026  87,543 unlisted options ex @ \$0.05 exp 31/5/2027</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of shares and free attaching options pursuant to non-renounceable entitlement offer.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Actinogen Medical Limited</b>
<b>ABN</b>	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Dr Steven Gourlay</b>
<b>Date of last notice</b>	<b>1 December 2023</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	1. Direct 2. Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	2. SG Gourlay Nominees Pty Ltd <SF Gourlay Family A/C> - Director of trustee and beneficiary of trust
<b>Date of change</b>	5 June 2024
<b>No. of securities held prior to change</b>	1. 68,362,300 fully paid ordinary shares issued pursuant to Employee Share Loan Plan. 4,155,727 fully paid ordinary shares. 702,864 unlisted options ex @ \$0.0375 exp 11/9/2026 2. 19,276,787 fully paid ordinary shares. 1,739,783 unlisted options ex @ \$0.0375 exp 11/9/2026
<b>Class</b>	Fully paid ordinary shares Unlisted options ex @ \$0.05 exp 31/5/2027
<b>Number acquired</b>	1. 3,514,880 fully paid ordinary shares 1,757,440 unlisted options ex @ \$0.05 exp 31/5/2027 2. 1,285,120 fully paid ordinary shares 642,560 unlisted options ex @ \$0.05 exp 31/5/2027
<b>Number disposed</b>	-

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration includes brokerage/gst</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$120,000
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>68,362,300 fully paid ordinary shares issued pursuant to Employee Share Loan Plan.  7,670,607 fully paid ordinary shares.  702,864 unlisted options ex @ \$0.0375 exp 11/9/2026  1,757,440 unlisted options ex @ \$0.05 exp 31/5/2027</li> <li>20,561,907 fully paid ordinary shares.  1,739,783 unlisted options ex @ \$0.0375 exp 11/9/2026  642,560 unlisted options ex @ \$0.05 exp 31/5/2027</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of shares and free attaching options pursuant to non-renounceable entitlement offer.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Actinogen Medical Limited</b>
<b>ABN</b>	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Dr George Morstyn</b>
<b>Date of last notice</b>	<b>1 December 2023</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	1. Direct 2. Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	2. HSBC Custody Nominees (Australia) Limited <A/C 2> - beneficiary
<b>Date of change</b>	5 June 2024
<b>No. of securities held prior to change</b>	1. 2,321,833 fully paid ordinary shares 5,500,000 fully paid ordinary shares issued pursuant to Employee Share Loan Plan. 299,805 unlisted options ex @ \$0.0375 exp 11/9/2026 2. 3,404,537 fully paid ordinary shares. 307,269 unlisted options ex @ \$0.0375 exp 11/9/2026.
<b>Class</b>	Fully paid ordinary shares Unlisted options ex @ \$0.05 exp 31/5/2027
<b>Number acquired</b>	1. 521,456 fully paid ordinary shares 260,728 unlisted options ex @ \$0.05 exp 31/5/2027 2. 226,969 fully paid ordinary shares 113,485 unlisted options ex @ \$0.05 exp 31/5/2027
<b>Number disposed</b>	-

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration includes brokerage/gst</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$18,710.65
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. 2,843,289 fully paid ordinary shares  5,500,000 fully paid ordinary shares issued pursuant to Employee Share Loan Plan.  299,805 unlisted options ex @ \$0.0375 exp 11/9/2026  260,728 unlisted options ex @ \$0.05 exp 31/5/2027</li> <li>2. 3,631,506 fully paid ordinary shares.  307,269 unlisted options ex @ \$0.0375 exp 11/9/2026.  113,485 unlisted options ex @ \$0.05 exp 31/5/2027</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of shares and free attaching options pursuant to non-renounceable entitlement offer.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Actinogen Medical Limited</b>
<b>ABN</b>	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Mr Malcolm McComas</b>
<b>Date of last notice</b>	<b>5 April 2024</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	1. Direct 2. Indirect 3. Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	2. Bunyula Super Pty Ltd <Bunyula Super Fund A/C> - director related entity and contingent beneficial interest 3. McComas Capital Pty Ltd <McComas Family A/C> - controller of trustee & a beneficiary of the trust
<b>Date of change</b>	5 June 2024
<b>No. of securities held prior to change</b>	1. 4,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan 2. 1,003,330 fully paid ordinary shares 90,554 unlisted options ex @ \$0.0375 exp 11/9/2026 3. 1,000,000 fully paid ordinary shares issued pursuant to Employee Share Plan 220,265 fully paid ordinary shares 110,133 unlisted options ex @ \$0.0375 exp 11/9/2026
<b>Class</b>	Fully paid ordinary shares Unlisted options ex @ \$0.05 exp 31/5/2027
<b>Number acquired</b>	1. 300,000 fully paid ordinary shares 150,000 unlisted options ex @ \$0.05 exp 31/5/2027 2. 66,889 fully paid ordinary shares 33,445 unlisted options ex @ \$0.05 exp 31/5/2027 3. 81,352 fully paid ordinary shares 40,676 unlisted options ex @ \$0.05 exp 31/5/2027
<b>Number disposed</b>	-

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration includes brokerage/gst</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$11,206.03
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. 4,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan  300,000 fully paid ordinary shares  150,000 unlisted options ex @ \$0.05 exp 31/5/2027</li> <li>2. 1,070,219 fully paid ordinary shares  90,554 unlisted options ex @ \$0.0375 exp 11/9/2026  33,445 unlisted options ex @ \$0.05 exp 31/5/2027</li> <li>3. 1,000,000 fully paid ordinary shares issued pursuant to Employee Share Plan  301,617 fully paid ordinary shares  110,133 unlisted options ex @ \$0.0375 exp 11/9/2026  40,676 unlisted options ex @ \$0.05 exp 31/5/2027</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of shares and free attaching options pursuant to non-renounceable entitlement offer.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.



# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Actinogen Medical Limited</b>
<b>ABN</b>	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Dr Nicki Vasquez</b>
<b>Date of last notice</b>	<b>1 December 2023</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	5 June 2024
<b>No. of securities held prior to change</b>	5,500,000 fully paid ordinary shares issued pursuant to Employee Share Loan Plan
<b>Class</b>	Fully paid ordinary shares Unlisted options ex @ \$0.05 exp 31/5/2027
<b>Number acquired</b>	366,667 fully paid ordinary shares 183,334 unlisted options ex @ \$0.05 exp 31/5/2027
<b>Number disposed</b>	-
<b>Value/Consideration includes brokerage/gst</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$9,166.68

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	5,500,000 fully paid ordinary shares issued pursuant to Employee Share Loan Plan 366,667 fully paid ordinary shares 183,334 unlisted options ex @ \$0.05 exp 31/5/2027
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares and free attaching options pursuant to non-renounceable entitlement offer.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.